Roche has dipped its toe in the M&A water with an agreement to buy US biotech 89bio and its late-stage candidate for metabolic dysfunction-associated steatohepatitis (MASH). The $14.50-per-share deal ...
Driven by a surging pipeline, the MASH therapeutic landscape is radically transforming as more drugs reach clinical trials. While Madrigal's Rezdiffra marked a groundbreaking first approval, it also ...
Editors and writers independently select products unless marked Sponsored or Promoted. Sponsored content is a paid ad, while content marked Promoted is chosen by Ziff Davis leadership. We may earn an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback